Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$71.06 +2.45%

+$1.58 today

Market cap
$481.56M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.12M

Average 0.17M

Returns on capital

Monopar Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-10.0%

avg -63.6%

ROIC

-12.1%

avg -64.8%

ROA

-9.7%

avg -56.3%

Analysis

ROA is currently the strongest return metric at -9.7% versus its period average of -56.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Chandler D. Robinson

Co-Founder, Chief Executive Officer, President & DirectorUSD 1.67M42——

Andrew J. Cittadine

Chief Operating OfficerUSD 985K54——

Quan Anh Vu

CFO, Principal accounting officer, Principal financial officer, Secretary & TreasurerUSD 623.51K542.65K0.04%

Christopher Starr

Co-Founder & Independent Executive Chairman of the BoardUSD 200K74——

Jeffrey D. Kent FACG FACP

Executive Vice President of Head of Medical Affairs—64——

Susan Rodriguez

Chief Commercial & Strategy Officer—640<0.01%

Patrice Rioux

Acting Chief Medical Officer—750<0.01%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$104,925.00

Sells

36

$5.68M

Net Transaction Value

−$5.57M

Net selling

Most Active

Tsuchimoto Kim R

16 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 4, 26

Tsuchimoto Kim R

Direct

Sell$91.6K
Nov 4, 26

Tsuchimoto Kim R

Direct

Sell$71.1K
Nov 4, 26

Tsuchimoto Kim R

Direct

Sell$43.3K
Nov 2, 26

Tsuchimoto Kim R

Direct

Sell$84K
Nov 2, 26

Anderson Raymond

Direct

Sell$105.2K
Nov 2, 26

Anderson Raymond

Direct

Sell$13.7K
Nov 2, 26

Anderson Raymond

Direct

Sell$40.2K
Nov 2, 26

Anderson Raymond

Direct

Sell$55.6K
Oct 1, 26

STARR CHRISTOPHER M

Direct

Sell$361.6K
Oct 1, 26

STARR CHRISTOPHER M

Direct

Sell$234.1K

1–10 of 37

Summary

Insiders reported 1 buys worth $104,925.00 and 36 sells worth $5.68M over the last 12 months. That adds up to net selling of $5.57M. Tsuchimoto Kim R was the most active insider with 16 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Monopar Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MNPR's management, answered from reported figures.

Who manages MNPR?

Monopar Therapeutics Inc. (MNPR) lists 7 active executives. The top listed executive is Chandler D. Robinson, Co-Founder, Chief Executive Officer, President & Director.

Are MNPR insiders buying or selling?

Recent insider activity shows net selling of $32.45M.